GSA Capital Partners LLP Acquires Shares of 38,500 Adaptive Biotechnologies Corporation $ADPT

GSA Capital Partners LLP bought a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 38,500 shares of the company’s stock, valued at approximately $826,000.

Other large investors have also modified their holdings of the company. Ameriprise Financial Inc. lifted its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at about $65,942,000. Geode Capital Management LLC lifted its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares in the last quarter. Finally, State Street Corp lifted its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after purchasing an additional 102,362 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Insiders Place Their Bets

In other news, insider Francis Lo sold 44,838 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total value of $1,012,890.42. Following the transaction, the insider owned 230,713 shares of the company’s stock, valued at $5,211,806.67. This represents a 16.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares in the company, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,306,971 shares of company stock worth $27,894,120 in the last three months. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of analyst reports. Morgan Stanley upped their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Guggenheim lifted their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. BTIG Research boosted their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. TD Cowen upped their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average target price of $24.42.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $24.56 on Wednesday. The firm has a 50 day simple moving average of $21.58 and a 200-day simple moving average of $17.19. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $26.16. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of -59.90 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same quarter in the prior year, the business earned ($0.17) EPS. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. On average, analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.